Previous 10 | Next 10 |
home / stock / bctxf / bctxf news
BERKELEY, Calif., and VANCOUVER, British Columbia, April 27, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
BERKELEY, Calif., and VANCOUVER, British Columbia, April 21, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced...
BERKELEY, Calif. and VANCOUVER, British Columbia, April 14, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced ...
THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES BERKELEY, Calif., and VANCOUVER, British Columbia, Feb. 21, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage...
The following slide deck was published by BriaCell Therapeutics Corp. in conjunction with this Read more ...
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 24, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that...
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 17, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces it...
Safety and early efficacy data were presented on December 12 th at 6:00 p.m. ET from the clinical trials of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: Continued additive or synergistic activity observed in combination study of Bri...
Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: Bria-IMT™ in combination with pembrolizumab (KEYTRUDA ® ; by Merck & Co., Inc.); Bria-IMT™...
News, Short Squeeze, Breakout and More Instantly...
BriaCell Therapeutics Company Name:
BCTXF Stock Symbol:
OTCMKTS Market:
BriaCell Therapeutics Website:
Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, April 10-15 and May...
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies f...
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies f...